In view of the death of newborns and children due to phlegm syrup in Madhya Pradesh and Rajasthan, the Maharashtra Food and Drug Administration (FDA) has now banned the sale, distribution and use of Coldriff Syrup Batch number SR 13 with immediate effect. Those who have this syrup have been instructed to inform the drug control officials. At the same time, the Drugs Department of Uttar Pradesh has ordered an inquiry into cuff syrup. Currently, Coldrif Cuff Syrup has been banned in Madhya Pradesh, Kerala, Tamil Nadu, Maharashtra. So far, 16 children in Madhya Pradesh have lost their lives due to this syrup, while three children have died in Rajasthan.
Kapha syrup present in medical store will be investigated
The Assistant Commissioner of Uttar Pradesh has ordered the drug inspectors of all the districts to sample the phlegm syrup from the pharma company to the medical store and seize the identified deadly phlegm syrup.
UP Assistant Commissioner (Drugs) has issued strict instructions to all the drug inspectors of the state with immediate effect. This action is mainly taken after a letter received from the Madhya Pradesh State License Authority, which has found adulteration of harmful elements called Diethylene Glycol in a cuff syrup manufactured by Messrs Sresan Pharmaceutical, Kanchipuram (Tamil Nadu). This element can be fatal for patients.
What is said in the instructions issued?
-If the Coldrif Syrup (batch number SR-13) or any other cuff syrup is found in the Cold Sale Instruments (Medical Store) and Government/Non-Government Hospitals, or any other cuff syrup is found, then the sample is taken and the purchase of the purchase should be prohibited immediately.
-Take necessary preventive action by raising samples of phlegm syrup available in all medical stores and hospitals.
All the samples of the collected cuff syrup should be immediately sent to the Lucknow laboratory for testing.
-Before collecting the mumps, the authorities must ensure that the same medicine (similar medicine and batch number) sample is not compiled more than once.
-Along with cuff syrup from the manufacturing units running in Ilake, a sample of Propylene Glycol used in it should also be sent to Lucknow laboratory for examination.
-FSDA has asked to strictly ensure these instructions. A copy of the letter has been sent to many higher officials and organizations in this regard.
Simultaneously, the Managing Director of UP Medical Supplies Corporation has been requested that if any phlegm syrup of Messrs Srasan Pharmaceutical is available in their reserves, then stop the distribution of its distribution.
-The department has requested the organizations of chemists and medical store operators to provide information about the stock of medicines (phlegm syrup) of the Messrs Srasan Pharmaceutical available to the drug vendors through their organization.
Input from news agency
—- End —-